Search

Showing total 284 results

Search Constraints

Start Over You searched for: Topic benzazepines Remove constraint Topic: benzazepines
284 results

Search Results

202. Efficacy of interventions to combat tobacco addiction: <scp>C</scp> ochrane update of 2012 reviews

203. Is Heart Rate a Norepiphenomenon in Heart Failure?

204. Ivabradine: A Review of Labeled and Off-Label Uses

205. Safety of Varenicline Among Smokers Enrolled in the Lung HIV Study

206. Concomitant Administration of Different Doses of Simvastatin with Ivabradine Influence on PAI-1 and Heart Rate in Normo- and Hypercholesterolaemic Rats

207. Mechanism-Based Therapeutics for Autosomal Dominant Polycystic Kidney Disease: Recent Progress and Future Prospects

208. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting

209. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan

210. V2receptor antagonism with tolvaptan in heart failure

211. Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptor

212. A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors.

213. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor

214. Distinguishing rotamers in N-trifluoroacetyl-3-benzazepine derivatives

215. Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat

216. [Vareniklin: a safe treatment of tobacco dependency for cardiovascular patients]

217. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews

218. [Determination of varenicline in the preparation Champix® with the use of two-dimensional capillary electrophoresis in connection with UV detection]

219. In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat

220. Receptor systems participating in nicotine-specific effects

221. The behavioural effects of pramipexole, a novel dopamine receptor agonist

222. Effectiveness of a Multi-Component Smoking Cessation Support Programme (McSCSP) for Patients with Severe Mental Disorders: Study Design

223. A systematic review of studies assessing the association between adherence to smoking cessation medication and treatment success

224. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity

225. How confidence intervals become confusion intervals

226. [The rare case of Bland-White-Garland syndrome in adult patient]

227. Use of the Patient Health Questionnaire-2 to predict suicidal ideations in patients taking varenicline

228. Very low rate and light smokers: smoking patterns and cessation-related behaviour in England, 2006-11

229. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

230. Tolvaptan for the treatment of heart failure: a review of the literature

231. ChemInform Abstract: Orally Active, Nonpeptide Vasopressin V2 Receptor Antagonists: A Novel Series of 1-(4-(Benzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H- benzazepines and Related Compounds

232. [Ivabradine in coronary heart disease: experimental and clinical pharmacology]

233. Improving the effectiveness of tobacco use cessation (TUC)

234. Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum

235. Dopamine D1 and opioid receptor binding changes in the limbic system of sleep deprived rats

236. Varenicline in the management of smoking cessation: a single technology appraisal

237. Multimodal techniques for smoking cessation: a review of their efficacy and utilisation and clinical practice guidelines

238. Sleep deprivation increases dopamine D1 receptor antagonist [3H]SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system

239. Recognition and treatment of hyponatremia in acutely ill hospitalized patients

240. Study into a possible mechanism responsible for the antidepressant-like activity of the selective 5-HT6 receptor antagonist SB-399885 in rats

241. Kicking butts: smoking cessation update

242. Fluorescence studies reveal heterodimerization of dopamine D1 and D2 receptors in the plasma membrane

243. Expression of behavioral sensitization to the cocaine-like fungicide triadimefon is blocked by pretreatment with AMPA, NMDA and DA D1 receptor antagonists

244. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus

245. Effects of nonpeptide V1a and V2 antagonists on blood pressure fast oscillations in conscious rats

246. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine

247. Determination of Dopamine D1 receptors in the human uveo-scleral tissue by light microscope autoradiography

248. Efficient synthesis of (S)-4-phthalimido-1,3,4,5-tetrahydro-8-(2,6-dichlorobenzyloxy)- 3-oxo-2H-2-benzazepin-2-acetic acid (PHt-Hba(2,6-Cl2-Bn)-Gly-OH)

249. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine

250. The influence of endogenous dopamine levels on the density of [3H]SCH23390-binding sites in the brain of the honey bee, Apis mellifera L